8-K: Nektar Therapeutics Reports Third Quarter 2024 Financial Results, Advances Pipeline

Nektar Therapeutics announced its third quarter 2024 financial results, highlighting progress in its clinical pipeline and a strategic sale of its commercial PEGylation manufacturing business.

Summary

• Nektar Therapeutics reported its financial results for the third quarter of 2024, with revenue remaining consistent at $24.1 million compared to the same period in 2023.
• The company's cash and investments totaled $249.0 million as of September 30, 2024, down from $329.4 million at the end of 2023, but are expected to fund operations into the fourth quarter of 2026.
• Total operating costs and expenses decreased to $58.5 million in Q3 2024 from $69.0 million in Q3 2023, primarily due to reduced restructuring and impairment costs.
• Research and development expenses increased to $35.0 million in Q3 2024 from $24.1 million in Q3 2023, driven by the development of rezpegaldesleukin and NKTR-0165.
• The net loss for the third quarter of 2024 was $37.1 million, or $0.18 per share, compared to a net loss of $45.8 million, or $0.24 per share, in the same quarter of 2023.
• Nektar is selling its commercial PEGylation manufacturing business for $90 million, consisting of $70 million in cash and $20 million in equity in the new company, with the deal expected to close by December 2, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the progress in the clinical pipeline, the strategic sale of the manufacturing business, and the reduction in operating costs. However, the company is still operating at a loss and has seen a decrease in cash reserves, which tempers the overall sentiment.

Positives

• Nektar's cash runway extends into the fourth quarter of 2026, providing financial stability.
• The company is making significant progress in its clinical pipeline, particularly with rezpegaldesleukin.
• Operating costs and expenses have decreased, indicating improved cost management.
• The sale of the PEGylation manufacturing business provides a cash infusion of $70 million and equity in the new company.
• Positive clinical data for rezpegaldesleukin in atopic dermatitis and psoriasis was published.
• The company is advancing multiple programs, including NKTR-0165, NKTR-0166, and NKTR-255.

Negatives

• Cash and investments decreased from $329.4 million at the end of 2023 to $249.0 million as of September 30, 2024.
• The company continues to operate at a loss, with a net loss of $37.1 million in Q3 2024.
• Research and development expenses increased, reflecting higher investment in clinical programs.
• Non-cash restructuring and impairment charges were $14.3 million for the first nine months of 2024, related to the declining San Francisco commercial real estate market.

Risks

• Clinical trials for rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255 are subject to risks, including negative safety and efficacy findings.
• The timing of clinical trials and data availability may be delayed or unsuccessful due to various factors.
• There is a risk that patents may not be issued or enforced, or that additional intellectual property licenses may be required.
• The sale of the PEGylation manufacturing business is subject to customary closing conditions and costs.

Future Outlook

Nektar expects its cash and marketable securities to support strategic development activities and operations into the fourth quarter of 2026. The company anticipates topline data from the Phase 2b studies of rezpegaldesleukin in the first and second halves of 2025. At least one of the earlier stage TNFR2 antibody and bispecific programs is slated to enter the clinic next year.

Management Comments

• We made excellent progress this quarter advancing our I&I pipeline, including the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata, said Howard W. Robin, President and CEO of Nektar.
• We see rapid enrollment in the 400-patient atopic dermatitis study for rezpegaldesleukin, and we remain on track for topline data in the first half of 2025.
• Our Phase 2 study in alopecia areata is also enrolling nicely with topline data expected in the second half of 2025.
• Beyond rezpegaldesleukin, we are focused on advancing our earlier stage TNFR2 antibody and bispecific programs, NKTR-0165 and NKTR-0166, with at least one of these slated to enter the clinic next year, continued Robin.

Industry Context

Nektar's focus on immunology and inflammatory diseases aligns with a growing trend in the biotechnology industry. The development of novel therapies for conditions like atopic dermatitis and alopecia areata is a key area of interest. The sale of the manufacturing business is a strategic move to focus on core drug development activities.

Comparison to Industry Standards

• Nektar's revenue is relatively modest compared to larger pharmaceutical companies, but is typical for a clinical-stage biotech company.
• The company's R&D spending is significant, reflecting its focus on drug development, which is common in the biotech sector.
• The net loss is also typical for a company in this stage of development, as they are investing heavily in research and clinical trials.
• The sale of the manufacturing business is a strategic move to streamline operations and focus on core competencies, similar to what other biotech companies have done.
• The 83% improvement in EASI score for atopic dermatitis patients receiving high dose rezpegaldesleukin is a strong result compared to other treatments in the market, such as Dupixent, which typically shows a 70-75% improvement in EASI scores.

Stakeholder Impact

• Shareholders may view the progress in the clinical pipeline and the sale of the manufacturing business positively.
• Employees at the Huntsville facility will be offered employment at the new portfolio company, ensuring continuity.
• Customers of the PEGylation manufacturing business will experience a transition to a new company, but with continued supply agreements.
• Creditors may be reassured by the company's cash runway and strategic moves.

Next Steps

• Nektar will continue to advance its Phase 2b studies for rezpegaldesleukin in atopic dermatitis and alopecia areata.
• The company will advance its earlier stage TNFR2 antibody and bispecific programs, NKTR-0165 and NKTR-0166.
• Nektar will present preclinical data for NKTR-422 at the 2024 ACR Convergence Meeting.
• The sale of the PEGylation manufacturing business is expected to close by December 2, 2024.
• Nektar will continue to present data at medical meetings.

Key Dates

Keywords

Nektar Therapeutics, rezpegaldesleukin, NKTR-358, atopic dermatitis, alopecia areata, immunology, clinical trials, biotechnology, financial results, PEGylation, NKTR-0165, NKTR-0166, NKTR-422, NKTR-255